Indiana Trust & Investment Management CO Grows Stock Holdings in Danaher Co. (NYSE:DHR)

Indiana Trust & Investment Management CO increased its stake in Danaher Co. (NYSE:DHR) by 9.9% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 758 shares of the conglomerate’s stock after buying an additional 68 shares during the quarter. Indiana Trust & Investment Management CO’s holdings in Danaher were worth $189,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Cary Street Partners Investment Advisory LLC increased its position in shares of Danaher by 20.2% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after acquiring an additional 1,533 shares in the last quarter. First Citizens Bank & Trust Co. increased its holdings in shares of Danaher by 0.6% in the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after purchasing an additional 149 shares in the last quarter. Cercano Management LLC raised its stake in shares of Danaher by 11.4% in the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after purchasing an additional 20,715 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Danaher by 48.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after purchasing an additional 96,395 shares in the last quarter. Finally, Caden Capital Partners LP boosted its position in shares of Danaher by 12.4% during the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after buying an additional 15,313 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the transaction, the senior vice president now owns 29,830 shares in the company, valued at $7,457,798.30. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at $28,908,273.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 148,783 shares of company stock valued at $37,536,717. 11.10% of the stock is owned by company insiders.

Danaher Price Performance

Shares of DHR traded down $1.73 during mid-day trading on Friday, reaching $250.03. The stock had a trading volume of 4,638,276 shares, compared to its average volume of 2,849,973. The business has a fifty day moving average of $255.36 and a 200 day moving average of $246.19. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The firm has a market cap of $185.19 billion, a price-to-earnings ratio of 42.09, a PEG ratio of 3.88 and a beta of 0.85. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $269.11.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the previous year, the company earned $2.36 EPS. Danaher’s revenue for the quarter was down 2.6% on a year-over-year basis. Equities analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio is currently 18.31%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday. TD Cowen increased their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Jefferies Financial Group initiated coverage on shares of Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. Citigroup raised their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Robert W. Baird upped their price objective on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $269.29.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.